别名 ISGF-3、signal transducer and activator of transcription 1、Signal transducer and activator of transcription 1-alpha/beta + [6] |
简介 Signal transducer and transcription activator that mediates cellular responses to interferons (IFNs), cytokine KITLG/SCF and other cytokines and other growth factors (PubMed:34508746, PubMed:35568036). Following type I IFN (IFN-alpha and IFN-beta) binding to cell surface receptors, signaling via protein kinases leads to activation of Jak kinases (TYK2 and JAK1) and to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerize and associate with ISGF3G/IRF-9 to form a complex termed ISGF3 transcription factor, that enters the nucleus (PubMed:28753426, PubMed:35568036). ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of IFN-stimulated genes (ISG), which drive the cell in an antiviral state. In response to type II IFN (IFN-gamma), STAT1 is tyrosine- and serine-phosphorylated (PubMed:26479788). It then forms a homodimer termed IFN-gamma-activated factor (GAF), migrates into the nucleus and binds to the IFN gamma activated sequence (GAS) to drive the expression of the target genes, inducing a cellular antiviral state. Becomes activated in response to KITLG/SCF and KIT signaling. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4. |
靶点 |
作用机制 STAT1抑制剂 [+1] |
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 STAT1调节剂 |
在研机构- |
原研机构 |
在研适应症- |
非在研适应症 |
最高研发阶段终止 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
作用机制 HMOX1调节剂 [+2] |
在研机构- |
在研适应症- |
非在研适应症 |
最高研发阶段无进展 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2007-01-23 |
申办/合作机构 |
开始日期2007-01-23 |
申办/合作机构 |
开始日期2007-01-23 |
申办/合作机构 |